Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Author:
Publisher
Elsevier BV
Subject
General Medicine
Reference7 articles.
1. Planning chemical syntheses with deep neural networks and symbolic AI;Segler;Nature,2018
2. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov;Zhao;BioRxiv,2020
3. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding;Lu;Lancet,2020
4. Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment;Pu;Antiviral Res,2018
Cited by 1155 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Antiviral therapy for COVID-19;COVID-19: An Update;2024-09-01
2. Repurposed Drugs during the Outbreak of Pandemic COVID-19: A Mini-Review on Their Molecular Structures and Hit-and-Trial Results;ACS Omega;2024-08-20
3. Expression, Purification, and Evaluation of Antibody Responses and Antibody-Immunogen Complex Simulation of a Designed Multi-Epitope Vaccine against SARS-COV-2;Protein & Peptide Letters;2024-08-19
4. Effect of 28 days treatment of baricitinib on mechanical allodynia, osteopenia, and loss of nerve fibers in an experimental model of type-1 diabetes mellitus;Pharmacological Reports;2024-08-19
5. Safety of CoronaVac and ChAdOx1 vaccines against SARS-CoV-2 in patients with rheumatoid arthritis: data from the Brazilian multicentric study safer;Advances in Rheumatology;2024-08-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3